JD
Therapeutic Areas
Tectonic Therapeutic Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TX000045 (TX45) | Heart Failure with Preserved Ejection Fraction (HFpEF) / Group 2 Pulmonary Hypertension | Phase 1 |
| Relaxin Program | Group 2 Pulmonary Hypertension | Preclinical |
| Undisclosed Program | Hereditary Hemorrhagic Telangiectasia (HHT) | Discovery |
Leadership Team at Tectonic Therapeutic
AR
Alise Reicin
President and CEO, Director
DL
Daniel Lochner
Chief Financial Officer
PM
Peter McNamara
Chief Scientific Officer
AM
Anthony Muslin
Chief Development Officer
MK
Marcella K Ruddy
Chief Medical Officer
MS
Marc Schwabish
Chief Business Officer
GP
Geraldine Peters-Wiles
Senior Vice President, Human Resources
BR
Barry Rubenstein
Senior Vice President, People & Culture
TA
Timothy A. Springer
Co-Founder, Board Director
AC
Andrew C. Kruse
Co-Founder